Related Experiment Video
Updated: Jul 9, 2025
11:15
A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
Published on: May 6, 2018
10.2K
Enhancing osteosarcoma therapy through aluminium hydroxide nanosheets-enabled macrophage modulation.
Min Cheng1, Yi Jiang1, Ying Wang1
1College of Biotechnology and Pharmaceutical Engineering, Nanjing Tech University, Nanjing 211816, China.
International Journal of Pharmaceutics
|December 3, 2023
Summary
New nanosheets co-deliver chemotherapy and immune modulators, enhancing osteosarcoma treatment by activating macrophages. This approach offers a promising strategy for recurrent and metastatic osteosarcoma.
Area of Science:
- Biomaterials Science
- Cancer Therapy
- Immunology
Background:
- Chemotherapy for osteosarcoma has stagnated, particularly for metastatic and recurrent cases.
- Tumor microenvironment modulation, especially macrophage manipulation, presents therapeutic opportunities.
Purpose of the Study:
- To develop a novel nanosheet system for co-delivery of doxorubicin and zoledronic acid.
- To evaluate the efficacy of this system in osteosarcoma treatment and macrophage modulation.
Main Methods:
- Fabrication of aluminium hydroxide nanosheets (nAl) with high positive surface charge.
- Co-loading of doxorubicin (DOX) and zoledronic acid (ZA) onto nAl, forming nAl/ZD.
- Assessment of nAl/ZD's cytotoxicity against LM8 osteosarcoma cells.
- Evaluation of M1 polarization induction in RAW 264.7 macrophages.
- Testing the antitumour effect in a co-culture model.
Main Results:
- nAl/ZD demonstrated efficient payload delivery (37% ZA, 8.5% DOX).
- The system exhibited significant inhibition of LM8 osteosarcoma cell growth.
- nAl/ZD preferentially induced M1 polarization in macrophages.
- Macrophage activation via nAl/ZD enhanced the antitumour effect in a co-culture system.
Conclusions:
- Aluminium hydroxide nanosheets are effective for co-delivering chemotherapy and immune modulators.
- The developed nAl/ZD system shows potential for treating osteosarcoma by modulating the tumor microenvironment.
- This strategy offers a new avenue for overcoming challenges in osteosarcoma treatment.
